Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.13
    -0.32 (-3.39%)

    Market Cap: $850.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Syndax Pharmaceuticals Inc (SNDX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 2, 2026. Financial statements from company filings, amounts in US dollars.

    Syndax Pharmaceuticals reported revenue of $172.35M for the fiscal year ended Dec 31, 2025, up 627.8% from the year before. That year, net income was -$285.42M with a net margin of -165.6%, operating cash flow was -$322.98M and free cash flow was -$323.17M. The quarter ended Sep 30, 2026 had revenue of $83.30M and net income of -$49.43M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $1.22M, a compound annual rate of 73.3%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$172.35M+627.8%96.0%-158.4%-165.6%
    Dec 2024$23.68MN/A96.5%-1434.4%-1346.1%
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0-100.0%N/AN/AN/A
    Dec 2021$139.71M+9109.6%100.0%18.8%17.8%
    Dec 2020$1.52M0.0%100.0%-4708.2%-4822.5%
    Dec 2019$1.52M0.0%100.0%-3792.9%-3694.6%
    Dec 2018$1.52M-28.0%100.0%-5001.7%-4875.5%
    Dec 2017$2.11M+72.8%100.0%-2939.0%-2884.3%
    Dec 2016$1.22MN/A100.0%-3587.4%-3645.2%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$172.35M$23.68M$0$0$139.71M$1.52M$1.52M$1.52M$2.11M$1.22M
    Cost of revenue$6.97M$826.00K$0$0$0$0$0$0$0$0
    Gross profit$165.38M$22.85M$0$0$139.71M$1.52M$1.52M$1.52M$2.11M$1.22M
    Research and development$258.78M$241.65M$163.03M$118.50M$88.25M$50.44M$42.99M$60.11M$48.20M$31.66M
    Operating income-$273.08M-$339.67M-$229.95M-$151.76M$26.22M-$71.42M-$57.54M-$75.88M-$61.95M-$43.77M
    Net income-$285.42M-$318.76M-$209.36M-$149.34M$24.93M-$73.16M-$56.05M-$73.96M-$60.80M-$44.47M
    EBITDAN/AN/AN/AN/A$27.07MN/AN/AN/AN/AN/A
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$83.30M$72.79M$64.86M$68.48M$45.87M$37.96M$20.04M$7.68M$12.50M$3.50M$0$536.00K
    Gross profit$69.30M$69.58M$62.23M$65.78M$43.77M$36.68M$19.16M$6.85M$12.50M$3.50M$0$268.00K
    Operating income-$41.90M-$39.99M-$34.20M-$62.55M-$57.43M-$69.35M-$83.76M-$96.36M-$89.58M-$74.22M-$79.51M-$77.91M
    Net income-$49.43M-$49.36M-$42.67M-$68.01M-$60.72M-$71.85M-$84.85M-$94.17M-$84.13M-$68.06M-$72.40M-$72.47M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $472.00K by $134.46M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$529.71M$724.82M$612.88M$497.24M$449.66M$300.61M$63.52M$83.94M$137.19M$109.01M
    Current assets$528.08M$603.06M$580.88M$489.79M$448.40M$298.86M$62.33M$83.35M$133.44M$108.51M
    Cash and equivalents$134.93M$154.08M$295.39M$74.36M$221.97M$115.24M$24.61M$33.77M$35.17M$23.84M
    Total liabilities$465.08M$436.69M$58.68M$29.79M$41.29M$48.42M$31.93M$30.89M$32.87M$24.87M
    Short-term debt$472.00K$12.12M$0$439.00K$362.00K$2.29M$0$13.01M$11.84M$6.38M
    Long-term debt$0$331.56M$0$0$19.89M$17.83M$0N/AN/AN/A
    Shareholder equity$64.63M$288.12M$554.20M$467.45M$408.37M$252.19M$31.60M$53.05M$104.32M$84.14M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$692.67M$703.65M$472.67M$529.71M$551.79M$596.15M$640.71M$724.82M$425.81M$476.95M$543.03M$612.88M
    Total liabilities$709.85M$688.55M$431.05M$465.08M$436.36M$438.73M$425.65M$436.69M$59.38M$42.61M$51.14M$58.68M
    Cash and equivalents$135.94M$336.48M$130.89M$134.93M$116.81M$108.64M$153.99M$154.08M$133.02M$105.40M$114.61M$295.39M
    Shareholder equity-$17.18M$15.10M$41.62M$64.63M$115.43M$157.42M$215.06M$288.12M$366.43M$434.34M$491.89M$554.20M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$322.98M-$274.90M-$160.60M-$133.68M$29.13M-$71.26M-$50.61M-$68.53M-$47.37M-$35.16M
    Capital expenditures$187.00K$0$0$225.00K$129.00K$0$0$187.00K$84.00K$261.00K
    Free cash flow-$323.17M-$274.90M-$160.60M-$133.90M$29.00M-$71.26M-$50.61M-$68.72M-$47.45M-$35.42M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/AN/A$2.60M
    Investing cash flow$290.04M-$219.78M$117.61M-$186.19M-$40.87M-$142.53M$12.78M$51.40M-$17.07M-$18.28M
    Financing cash flow$13.68M$353.37M$264.13M$172.25M$118.46M$304.42M$28.57M$15.73M$75.72M$54.20M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$27.25M-$30.27M-$50.34M-$69.49M-$70.53M-$87.80M-$95.16M-$57.39M-$62.32M-$71.64M-$83.55M-$41.35M
    Capital expendituresN/A$40.00K$0$56.00K$131.00K$0$0$0$0$0$0$0
    Free cash flowN/A-$30.31M-$50.34M-$69.54M-$70.67M-$87.80M-$95.16M-$57.39M-$62.32M-$71.64M-$83.55M-$41.35M
    Last 12 quarters

    Frequently Asked Questions About SNDX

    What is Syndax Pharmaceuticals' annual revenue?

    Syndax Pharmaceuticals reported revenue of $172.35M for the fiscal year ended Dec 31, 2025.

    How fast is Syndax Pharmaceuticals' revenue growing?

    Revenue was up 627.8% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Syndax Pharmaceuticals profitable?

    No. Syndax Pharmaceuticals reported net income of -$285.42M for the fiscal year ended Dec 31, 2025, with a net margin of -165.6%.

    How much free cash flow does SNDX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$322.98M minus capital expenditures of $187.00K produced free cash flow of -$323.17M.

    How much debt does Syndax Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $0, short-term debt of $472.00K and cash and equivalents of $134.93M.